杂志简称：mol cell proteomics
中文译名：《分子与细胞蛋白质组学》
收录属性：scie（2024版）, 目次收录（知网）,英文期刊,
自引率：4.10%
投稿方向：生物、biochemical research methods生化研究方法
SCI/E期刊基本信息
出版周期：月刊 地区：美国
中科院分区：2区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN 1535-9476;EISSN 1535-9484
杂志语言：英语
出版国家：美国
杂志官网 联系方式
出版地址：11200 ROCKVILLE PIKE,SUITE 302,ROCKVILLE,United States,MD,20852
杂志邮箱：
投稿网址：https://www.editorialmanager.com/mcpro/default1.aspx
杂志官方网址：https://www.sciencedirect.com/journal/molecular-and-cellular-proteomics
出版商网址：http://www.asbmb.org
杂志投稿要求
投稿须知【杂志社官方网站信息】
MOLECULAR & CELLULAR PROTEOMICS
Ethics in publishing
Please see our information on Ethics in publishing.
Authorship criteria
Adapted from the recommendation of the International Committee of Medical Journal Editors (ICMJE)
Authorship credit should be based on the following:
substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
drafting the article or substantively contributing to revisions in intellectual content;
final approval of the version to be published;
agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
All those designated as authors must meet all four criteria for authorship. Acquisition of funding or general supervision of the research group alone does not constitute authorship. It is expected that each author has made an important scientific contribution to the study and is thoroughly familiar with the original data. It is also expected that each author has read the complete manuscript and takes responsibility for its content and completeness. By accepting authorship, the author understands that if the paper, or any part thereof, is found to be faulty or in violation of ethical standards, they share responsibility with their co-authors.
Assignment of each author's contributions is requested as part of the online submission process.
"Group authorship" is allowed in which the name of the consortium or program is listed as an author, with members of the group listed in the Acknowledgments section. All listed members must meet the full criteria and requirements for authorship as described.
The Editor-in-Chief maintains discretion to allow or disallow inclusion of authors who are deceased. To facilitate review in each case, the contributions of these authors should be described in detail in the manuscript cover letter and within the online submission system.
All substantial changes in authorship (additions, removals, or change in order) that are requested after acceptance must be approved by the Associate Editor and all co-authors. Requests for changes must be made by the corresponding author, co-signed by all co-authors, and sent to the Associate Editor who handled the manuscript. For any requests to remove a co-author, the person who will be removed must also send a letter to the Associate Editor acknowledging this change.
ASBMB journals follow the ICJME recommendations for responsibilities of the corresponding author.
Studies involving human subjects or animals
Human subjects
All studies involving human subjects must be approved by the appropriate review board(s) and abide by the Declaration of Helsinki principles. A specific statement declaring approval and Helsinki compliance must be included in the Experimental Procedures section. Published studies that involve human subjects should not provide any identifying information (e.g., names, true initials, recognizable images) unless the information is essential for scientific purposes and the patient (or patient's parent/guardian) gives written informed consent for publication. If the patient is deceased, then the authors should seek consent from a relative. If such written consent is required, please download the form here and upload as additional Supplemental material for review only.
Animal and preclinical research studies
ASBMB encourages the reporting of animal data using the nomenclature and standards outlined in the ARRIVE (Animal in Research: Reporting In Vivo Experiments) guidelines, Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research PLoS Biol. 2010 Jun 29;8(6):e1000412. All studies must be approved by the appropriate review board(s) and a specific statement of such an approval must be made in the Experimental Procedures section.
Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Conflict of Interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in one of two places: 1. A summary conflict of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no conflicts of interest to declare then please state this: 'Conflicts of interest: none'. 2. Detailed disclosures as part of a separate Conflict of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in one of these locations. More information.